Iovance Biotherapeutics, Inc.IOVANASDAQ

Revenue (LTM)

$264M

+60.6% YoY

Net Income (LTM)

$-391M

-5.1% YoY

Free Cash Flow

$-336M

Revenue CAGR (5Y)

—

Marginsimproving

FCF($0.3B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	1	164↑13699.0%	264↑60.6%
Gross Profit	0	0	-10	40↑518.9%	256↑539.3%
Operating Income	-343	-399↓16.4%	-461↓15.5%	-395↑14.2%	-403↓2.0%
Net Income	-342	-396↓15.7%	-444↓12.2%	-372↑16.2%	-391↓5.1%
EBITDA	-329	-378↓14.9%	-427↓13.2%	-352↑17.7%	-357↓1.5%
EPS Diluted	-2.23	-2.49↓11.7%	-1.89↑24.1%	-1.28↑32.3%	-1.09↑14.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	78	232↑196.2%	115↓50.4%	116↑0.7%	163↑41.0%
Total Current Assets	508	479↓5.7%	308↓35.7%	457↑48.5%	443↓3.1%
Total Assets	777	664↓14.6%	780↑17.5%	910↑16.7%	913↑0.3%
Total Current Liabilities	89	91↑2.6%	110↑20.6%	122↑10.9%	138↑13.1%
Total Liabilities	156	164↑5.6%	196↑19.1%	200↑2.2%	215↑7.3%
Total Equity	622	500↓19.6%	585↑17.0%	710↑21.5%	699↓1.7%
Total Debt	72	85↑19.5%	76↓11.2%	58↓23.2%	48↓16.9%
Net Debt	-7	-146↓2084.0%	-39↑73.3%	-57↓47.2%	-115↓99.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-228	-293↓28.4%	-362↓23.6%	-353↑2.4%	-302↑14.3%
Capital Expenditure	-38	-20↑45.6%	-22↓9.1%	-11↑50.3%	-34↓205.7%
Free Cash Flow	-266	-313↓18.0%	-384↓22.6%	-364↑5.2%	-336↑7.6%
Stock-Based Comp	70	84↑20.4%	63↓25.5%	110↑75.1%	62↓43.8%
Net Change in Cash	11	154↑1242.6%	-57↓136.9%	-59↓4.3%	47↑180.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance